Roche’s Tecentriq gains first-line approval in NSCLC but Merck’s Keytruda dominates the space

Despite this latest approval for Roche, Merck was able to secure the same label for Keytruda as a first-line monotherapy in 2016 with comparable efficacy. Credit: Shutterstock



  • Mercks Keytruda